Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
ADGI

ADGI - Adagio Therapeutics, Inc. Stock Price, Fair Value and News

1.29USD+0.10 (+8.40%)Market Closed

Market Summary

ADGI
USD1.29+0.10
Market Closed
8.40%

ADGI Stock Price

View Fullscreen

ADGI RSI Chart

ADGI Valuation

Market Cap

153.9M

Price/Earnings (Trailing)

-0.74

Price/Free Cashflow

-0.84

ADGI Price/Earnings (Trailing)

ADGI Profitability

Return on Equity

-115.87%

Return on Assets

-95.99%

Free Cashflow Yield

-118.46%

ADGI Fundamentals

ADGI Earnings

Earnings (TTM)

-206.8M

Earnings Growth (Yr)

-23.14%

Earnings Growth (Qtr)

40.95%

Breaking Down ADGI Revenue

Last 7 days

21.7%

Last 30 days

-18.3%

Last 90 days

-52.4%

How does ADGI drawdown profile look like?

ADGI Financial Health

Current Ratio

5.77

ADGI Investor Care

Shares Dilution (1Y)

1.02%

Diluted EPS (TTM)

-1.87

Tracking the Latest Insider Buys and Sells of Adagio Therapeutics, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Sep 01, 2022
hering david
bought
36,160
4.52
8,000
chief executive officer
Aug 19, 2022
elia marc
bought
2,700,160
4.62
584,451
-
Aug 18, 2022
elia marc
bought
5,454,520
4.31
1,265,550
-
Aug 17, 2022
elia marc
bought
4,040,000
4.04
1,000,000
-
Mar 03, 2022
adimab, llc
sold
-
-
-1,158,090
-
Aug 10, 2021
mcguire terrance
bought
8,500,000
17.00
500,000
-
Aug 10, 2021
mcguire terrance
acquired
-
-
8,031,700
-
Aug 10, 2021
redmile group, llc
bought
24,990,000
17.00
1,470,000
-
Aug 10, 2021
redmile group, llc
acquired
-
-
1,920,960
-
Aug 10, 2021
adimab, llc
acquired
-
-
25,860,700
-

1–10 of 15

Which funds bought or sold ADGI recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 12, 2024
SG Americas Securities, LLC
added
198
-14,000
42,000
-%
Jul 09, 2024
TRUST CO OF VERMONT
sold off
-100
-5,550
-
-%
Jul 02, 2024
Modus Advisors, LLC
new
-
12,100
12,100
-%
May 16, 2024
Tidal Investments LLC
new
-
125,816
125,816
-%
May 16, 2024
JANE STREET GROUP, LLC
added
68.46
685,110
1,447,730
-%
May 15, 2024
Squarepoint Ops LLC
added
177
859,590
1,263,010
-%
May 15, 2024
Schonfeld Strategic Advisors LLC
new
-
186,590
186,590
-%
May 15, 2024
Man Group plc
new
-
630,573
630,573
-%
May 15, 2024
Point72 Asia (Singapore) Pte. Ltd.
added
4,102
326,407
333,448
0.09%
May 15, 2024
Bain Capital Life Sciences Investors, LLC
reduced
-7.1
357,606
7,990,200
0.64%

1–10 of 47

Are Funds Buying or Selling ADGI?

Are funds buying ADGI calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ADGI
No. of Funds

Unveiling Adagio Therapeutics, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
maverick capital ltd
8.5%
9,343,949
SC 13G
Feb 12, 2024
deep track capital, lp
7.56%
9e+06
SC 13G
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 22, 2024
adimab, llc
19.7%
21,687,906
SC 13D/A
Sep 11, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Aug 19, 2022
m28 capital management lp
8.50%
9,248,250
SC 13D/A
Jul 05, 2022
mithril ii lp
10.2%
11,241,580
SC 13D/A
Jun 24, 2022
population health equity partners iii, l.p.
33%
359,662
SC 13D/A
Jun 24, 2022
m28 capital management lp
5.78%
6,398,250
SC 13D/A

Recent SEC filings of Adagio Therapeutics, Inc.

View All Filings
Date Filed Form Type Document
Jun 14, 2024
8-K
Current Report
Jun 06, 2024
3
Insider Trading
Jun 06, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 31, 2024
8-K
Current Report
May 29, 2024
144
Notice of Insider Sale Intent
May 23, 2024
4
Insider Trading
May 23, 2024
3
Insider Trading
May 23, 2024
3
Insider Trading
May 23, 2024
4
Insider Trading

Adagio Therapeutics, Inc. News

Latest updates
Yahoo Finance22 months ago
RagingBull2 years ago
Investopedia2 years ago

Adagio Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22020Q4
Assets-6.0%215229275315351383425485556620686398117
  Current Assets-6.7%210225270310345377422481554617680396117
    Cash Equivalents-5.6%18920118212212692.00278475532542478393115
  Inventory-0.00------------
  Net PPE0.3%2.002.002.002.002.002.001.000.000.000.00---
Liabilities-28.5%37.0052.0028.0034.0024.0027.0047.0070.0097.0062.0053.0038.0013.00
  Current Liabilities-27.7%36.0050.0027.0033.0022.0025.0046.0068.0096.0062.0053.0038.0013.00
Shareholder's Equity0.6%178177246282327356377415459558633--
  Retained Earnings-5.9%-775-732-658-618-568-533-488-443-392-292-209-148-65.32
  Additional Paid-In Capital4.9%9549109059018968908668598528508424.000.00
Shares Outstanding8.2%11911011011010910910810810811120.006.006.00
Float----67.00---229-----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q3
Cashflow From Operations15.2%-50,214-59,240-35,352-37,391-41,181-47,404-56,142-57,392-59,049-73,212-54,213-33,570-23,741-13,428-1,143
  Share Based Compensation23.8%5,3794,3444,2644,6775,4005,9057,3996,3611,9837,8565,9793,3425871487.00
Cashflow From Investing-100.2%-14077,91895,13532,59575,036-138,813-140,837-17.0049,000137,916-188,627----
Cashflow From Financing27631.2%39,10114192.0027054214124674.0045.00-749328,600334,832-79,83949,720
  Buy Backs----1.00---2.002.00-----82.0085.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ADGI Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development[1]$ 31,160$ 27,201
Acquired in-process research and development[2]0825
Selling, general and administrative14,92911,045
Total operating expenses46,08939,071
Loss from operations(46,089)(39,071)
Other income:  
Other income, net2,5933,750
Total other income, net2,5933,750
Net loss(43,496)(35,321)
Other comprehensive income (loss)  
Unrealized gain on available-for-sale securities, net of tax1157
Comprehensive loss$ (43,495)$ (35,164)
Net loss per share attributable to common stockholders, basic$ (0.38)$ (0.32)
Net loss per share attributable to common stockholders,diluted$ (0.38)$ (0.32)
Weighted-average common shares outstanding, basic115,618,209108,785,519
Weighted-average common shares outstanding, diluted115,618,209108,785,519
[1]Includes related-party amounts of $1,135 and $2,960 for the three months ended March 31, 2024 and 2023, respectively (see Note 14).
[2]Includes related-party amounts of $0 and $375 for the three months ended March 31, 2024 and 2023, respectively (see Note 14).

ADGI Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 189,388$ 200,641
Inventory1090
Prepaid expenses and other current assets20,38624,240
Total current assets209,883224,881
Property and equipment, net1,9011,896
Operating lease right-of-use asset1,8272,229
Other non-current assets1,857175
Total assets215,468229,181
Current liabilities:  
Accounts payable1,1687,953
Accrued expenses34,00340,860
Operating lease liability, current1,1341,443
Other current liability4035
Total current liabilities36,34550,291
Operating lease liability, non-current625722
Other non-current liability0700
Total liabilities36,97051,713
Commitments and contingencies (Note 8)
Stockholders' equity (deficit):  
Preferred stock (undesignated), $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding at March 31, 2024 and December 31, 202300
Common stock, $0.0001 par value; 1,000,000,000 shares authorized, 119,221,230 shares issued and outstanding at March 31, 2024; 110,160,684 shares issued and outstanding at December 31, 20231211
Additional paid-in capital954,063909,539
Accumulated other comprehensive loss(12)(13)
Accumulated deficit(775,565)(732,069)
Total stockholders' equity178,498177,468
Total liabilities, preferred stock and stockholders' equity$ 215,468$ 229,181
ADGI
0
 WEBSITEhttps://adagiotx.com

Adagio Therapeutics, Inc. Frequently Asked Questions


What is the ticker symbol for Adagio Therapeutics, Inc.? What does ADGI stand for in stocks?

ADGI is the stock ticker symbol of Adagio Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Adagio Therapeutics, Inc. (ADGI)?

As of Mon Jul 15 2024, market cap of Adagio Therapeutics, Inc. is 153.92 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADGI stock?

You can check ADGI's fair value in chart for subscribers.

What is the fair value of ADGI stock?

You can check ADGI's fair value in chart for subscribers. The fair value of Adagio Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Adagio Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ADGI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Adagio Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether ADGI is over valued or under valued. Whether Adagio Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Adagio Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADGI.